Skip to content
FLFunding Landscape
Open·Ingested 90 days ago, not re-verified since

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Defense Health Agency Contracting Activity - DHACA

Go to the official application

Free. Verify your email, then we send one reminder only.

Download details (file)
Posted
May 4, 2026
Amount
$7,000,000
Closes
Sep 30, 2026 (in 58 days)

Get alerted when new grant funding like this opens.

Checking your account…

Free. Everyone sees new listings after 10 days. Unsubscribe anytime.

Classification and identifiers

Solicitation number
HT942526ALSRPCOBA
Assistance listing (CFDA)
12.420

Amount

$7,000,000

Who can apply

Open to all

About this opportunity

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitori...

Related opportunities

Refine this search